Interstitial Lung Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 years or older
- People who have been diagnosed with a scarring lung disease (called fibrotic ILD) confirmed by a detailed CT scan of the lungs — this includes conditions such as idiopathic pulmonary fibrosis, autoimmune-related lung scarring, chronic hypersensitivity pneumonitis, nonspecific interstitial pneumonia, occupational lung disease, or a combination of lung scarring and emphysema where the scarring is more extensive than the emphysema
- For Groups 1–3: People whose right-heart catheterisation (a heart and lung pressure test) has confirmed high blood pressure in the lungs (pulmonary hypertension), with specific pressure measurements meeting defined thresholds (confirm with trial site)
- For Group 1 specifically: People who are not currently using an inhaled medication called treprostinil (Tyvaso/Tyvaso DPI) at the time of enrolment
- For Group 2 specifically: People who either started Tyvaso/Tyvaso DPI at enrolment or started it no more than 90 days before enrolment
- For Group 3 specifically: People who have been taking Tyvaso/Tyvaso DPI at the time of enrolment and for more than 90 days before enrolment
- For Group 4 specifically: People whose right-heart catheterisation did not meet the full definition of pulmonary hypertension but did show a specific pressure reading within a defined range (confirm with trial site)
- People who are already taking part in other research studies may also be considered
- People who are willing and able to give informed consent and complete surveys in English or Spanish
Who may not be able to join:
- People with a confirmed diagnosis of pulmonary hypertension classified as Group 1, 2, 4, or 5 — though in some cases where a person has both scarring-lung-related pulmonary hypertension and another type, the treating investigator may consider enrolment if the lung scarring is judged to be the main cause (confirm with trial site)
- People with Group 3 pulmonary hypertension caused by lung diseases or low oxygen levels other than the fibrotic lung diseases listed in the inclusion criteria
- People who are currently using an inhaled form of treprostinil called Yutrepia at the time of enrolment — note that people using other types of pulmonary hypertension treatments may still be considered
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 919-485-8350
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Baseline characteristics as described by demographics, medical history, ILD history, PH history, family history (comorbidities), and diagnostic right heart catheterization values.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.